Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India
- 162 Downloads
Interleukin-18 (IL-18) is one of the immunomodulatory cytokines that plays an important role in cellular functions against tumor development and progression. IL-18 (-607) C/A and (-0137) G/C gene promoter polymorphisms and their haplotypes variants are associated with risk of various cancers. We evaluated a possible association of IL-18 (-607) C/A and (-137) G/C gene promoter polymorphisms in the susceptibility to oral squamous cell carcinoma (OSCC). A total number of 272 patients with OSCC and 185 healthy volunteers were genotyped for the IL-18 (-607) C/A and (-137) G/C polymorphism. Polymorphism variants were examined by using tetra-primer amplification refractory mutation system (T-ARMS). Genotype frequencies were evaluated by chi-square test and odds ratio (OR) relative risk. IL-18 (-137) G/C gene polymorphism was significantly associated with the risk of OSCC as compared to healthy volunteers (genotype GG vs GC: OR 2.238; 95 % CI 1.455-3.441; p = 0.0003 and allele G vs C: OR 1.984; 95 % CI 1.335–2.947; p = 0.0007). The genotype and allele frequencies of the IL-18 promoter -607 C/A polymorphism in OSCC patients were not significantly different than that in healthy controls (p > 0.05). Our results suggest that IL-18 -137 G/C polymorphism is significantly associated with the progression of oral cancer but -607 C/A polymorphism is not associated with this.
KeywordsOral squamous cell carcinoma Cytokines Interleukin Inflammation Genotype
This work was financially supported by a grant from Indian Council of Medical Research (ICMR).
Conflicts of interest
- 1.World Health Organization. Strengthening the prevention of oral cancer: the WHO perspective. http://www.who.int/oral_health/publications/CDOE05_vol33_397_9/en/ (accessed on 26 Oct 2013)
- 2.International Agency for Research on Cancer. GLOBOCAN 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (accessed on 26 Oct 2013)
- 6.Nilkaeo A, Bhuvanath S. Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediat Inflamm. 2006;3:67120.Google Scholar
- 11.Ray JG, Ganguly M, Rao BS, Mukherjee S, Mahato B, et al. Clinico-epidemiological profile of oral potentially malignant and malignant conditions among areca nut, tobacco and alcohol users in Eastern India: a hospital based study. J Oral Maxillofac Pathol. 2013;17:45–50.PubMedCentralPubMedCrossRefGoogle Scholar
- 18.Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol. 2007;26:6138.Google Scholar
- 19.Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C. Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res. 2007;27:384953.Google Scholar
- 25.Taheri M, Hashemi-Shahri SM, Hamzehnejadi M, Naderi M, Moazeni-Roodi A, Bahari G, et al. Lack of association between interleukin-18 -607 C/A gene polymorphism and pulmonary tuberculosis in Zahedan, southeast Iran. Prauge Med Rep. 2012;113:16–22.Google Scholar
- 36.Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Boil Regul Homoest Agents. 2000;14:275–7.Google Scholar
- 37.Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB. 1999;13:2195–202.Google Scholar
- 39.Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mizzanzanica D, et al. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. In J Cancer. 2002;98:873–8.Google Scholar